The management of clinical trials is a critical factor in ensuring that effective drugs are brought to market in the shortest time possible and, in the event that a candidate is ineffective, allowing sponsors to stop funding failed projects at the earliest juncture.
However, in a increasingly globalised market where trials are often carried out in multiple locations, according to rules imposed by several regional regulators, making development of an effective centralised management system a considerable challenge.
Additionally, with the US Food and Drug Administration (FDA) issuance of formal regulations on adaptive trials expected later this year the likelihood is that the trial procedure is going to become even more complex in years to come.
DZS believes that such factors are delaying the adoption of effective CTMS technologies by contract research organisations (CROs), meaning the studies are not being carried out as efficiently as they could be.
The New Jersey firm claims that ClinPlus CTMS, which will be officially launched at the Drug Information Association (DIA) conference in San Diego next week, improves productivity via enhanced patient and event tracking.
DSZ cites the technology’s out-of-variance warning system, which alerts trial professionals when patients are not adhering to correct procedure or when regulatory documents are lacking, as a key efficiency feature.
The firm explained that: “This capability enables resolution of queries within minutes rather than hours needed to find, and possibly miss these issues.”
DZS also claimed that because ClinPlus CTMS is a hosted solution it offers CROs and pharma sponsors a way of implementing effective data management and security for minimal IT investment and infrastructure spending.
The new technology expands DZS’ ClinPlus Solutions Suite of data management and coding technologies that are widely used in the contract research sector.